• Sep
  • 2021

NATCO Canada

Natco Pharma (Canada) Inc. announces the launch of PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid®

Read more >

  • Feb
  • 2021

NATCO Canada

NATCO launches NAT-Bendamustine powder for suspension 25mg and 100mg, in Canada

  • Jan
  • 2021

NATCO Canada

NATCO launches NAT-Abiraterone tablets 250mg, in Canada

  • Aug
  • 2021

NATCO Global

NATCO transfers Lenalidomide ANDA to Arrow

Read more >

  • Jun
  • 2021

NATCO Global

NATCO receives approval for Carfilzomib Vials ANDA (generic for KYPROLIS® ) in the US market

Read more >

  • May
  • 2021

NATCO Global

NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA®) ANDA in the US market

Read more >

  • May
  • 2021

NATCO Global

NATCO receives USFDA approval for Lenalidomide Capsules

Read more >

  • May
  • 2021

NATCO Global

NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment

Read more >

  • May
  • 2021

NATCO Global

NATCO signs Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India

Read more >

  • May
  • 2021

NATCO Global

NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

Read more >

  • Apr
  • 2021

NATCO Global

NATCO seeks Emergency approval of Molnupiravir capsules for Covid-19 treatment

Read more >

  • Mar
  • 2021

NATCO Global

NATCO receives final approval for Everolimus tablets (generic for Afinitor® ) for the US market

Read more >

  • Feb
  • 2021

NATCO Global

NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy

Read more >

  • Jan
  • 2021

NATCO Global

NATCO receives final approval for Everolimus tablets (generic for ZORTRESS9) in the US market

Read more >